Comparative Study of NXL104/ceftazidime versus comparator in adults with complicated urinary tract infections

Study identifier:NXL104/2001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Prospective, multicenter, investigator-blinded, randomized, comparative study estimate safety, tolerability, efficacy of NXL104/ceftazidime vs. comparator followed appropriate oral therapy treatment complicated UTI hosp adults

Medical condition

Complicated urinary tract infection

Phase

Phase 2

Healthy volunteers

No

Study drug

NXL104/ceftazidime, Imipenem/Cilastatin

Sex

All

Actual Enrollment

137

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2008
Primary Completion Date: 01 Jun 2010
Study Completion Date: 01 Jul 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2011 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria